Abciximab biosimilar - Reliance Life Sciences

Drug Profile

Abciximab biosimilar - Reliance Life Sciences

Alternative Names: AbcixiRel; R-TPR-019

Latest Information Update: 30 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Reliance Life Sciences
  • Class Antiplatelets; Fab fragments; Ischaemic heart disorder therapies; Monoclonal antibodies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ischaemic heart disorders; Unstable angina pectoris

Most Recent Events

  • 30 Sep 2013 Launched for Ischaemic heart disorders (prevention) in India (IV)
  • 30 Sep 2013 Launched for Unstable angina pectoris in India (IV)
  • 26 Jun 2013 Reliance Life Sciences completes a phase III trial in Ischaemic heart disorders (Prevention) in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top